A Study to Assess the Safety, Tolerability and Anti-tumour Activity of Ascending Doses of Selumetinib in Combination With MEDI4736 and Selumetinib in Combination With MEDI4736 and Tremelimumab in Patients With Advanced Solid Tumours

Clinical trial NCT02586987 · COMPLETED

Trial details

NCT number: NCT02586987
Sponsor: AstraZeneca
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Lung Cancer Melanoma Head and Neck Carcinoma Gastroesophageal Cancer Breast Cancer Pancreatic Adenocarcinoma Colorectal Cancer Biliary Tract Cancer

Start date: 2015-12-28
Primary completion: 2018-07-25
Enrollment: 58

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.